Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative

Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San-Diego based ARS Pharmaceuticals.